This article is more than 5 years old. Information may no longer be current.

FDA grants orphan drug designation to PEGPH20 for pancreatic cancer

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA has granted orphan drug designation to pegylated recombinant human hyaluronidase for the treatment of pancreatic cancer, according to a press release.

Pegylated recombinant human hyaluronidase (PEGPH20, Halozyme Therapeutics) is an investigational drug being developed for the systemic treatment of hyaluronan-accumulating tumors, the release said.

“This designation follows the fast track designation and allows us to collaborate more closely with the FDA to facilitate development of PEGPH20 and is part of our core strategy to bring this therapy to patients as rapidly as possible,” Helen Torley, MB, ChB, president and CEO of Halozyme, said in the release. “Receiving orphan drug designation is an important milestone for this clinical development program.”

A phase 2 study of PEGPH20 in combination with gemcitabine (Gemzar, Eli Lilly) and nab-paclitaxel (Abraxane, Celgene) for metastatic pancreatic cancer treatment is currently under way, the release said.